A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
- Status
- COMPLETED
- Phase
- N/A
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Status
- RECRUITING
- Phase
- PHASE3
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]
- Status
- COMPLETED
- Phase
- N/A
Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
- Status
- RECRUITING
- Phase
- PHASE1
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Status
- RECRUITING
- Phase
- PHASE3
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE2
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
- Status
- RECRUITING
- Phase
- PHASE2
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
- Status
- RECRUITING
- Phase
- PHASE3
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
- Status
- RECRUITING
- Phase
- PHASE1
Ixovex-1 Single Agent and Combination Therapy
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE3